Your call: what does this data set support?

A provider calls the laboratory with this exact result set in hand and two questions: can the laboratory confirm metabolic syndrome, and is the CGM report showing a testing error because GMI and A1c do not match? Before answering either question, decide what the evidence in front of you actually supports and what it cannot establish.

On the metabolic-syndrome question, four independently scored criteria are met under either the 2001 ATP III or the 2009 harmonized version: triglycerides, HDL, blood pressure, and fasting glucose. This particular fasting glucose value of 118 mg/dL clears both versions' thresholds. Waist remains unscored because the population needed to choose its cutoff is not supplied. The answer has to name the criteria set used, and it is a laboratory pattern, not a diabetes diagnosis, since diabetes has its own separate thresholds that were not met here.

On the CGM question, data sufficiency is met (78% active time over 14 days, above the 70% threshold), so the TIR, TAR, and CV numbers are interpretable rather than noise. The 0.9-point gap between GMI and laboratory A1c can be explained in part by GMI’s 14-day estimate and A1c’s roughly 2-3 month window, but it does not prove either result is free of interference, red-cell effects, or missing-data limitations. The isolated overnight low on the one low-active-time day fits a compression artifact rather than confirmed hypoglycemia, and should be flagged as unconfirmed rather than reported as a hypoglycemic event.

Choose a defensible next laboratory action: report the discrete analyte values as measured, add an interpretive comment on the metabolic-syndrome pattern that explicitly names the criteria version and cut point applied, and note for the provider that the GMI-versus-A1c gap reflects different measurement windows as one possible contributor, not proof that either result is correct, while flagging the overnight low event as unconfirmed by fingerstick and consistent with sensor pressure rather than true hypoglycemia. Do not set device thresholds, adjust the sensor, or recommend a specific therapy change; that decision belongs to the treating clinician using device-specific instructions and current organizational criteria.

A defensible answer names its criteria version, confirms data sufficiency before trusting CGM metrics, and reviews uncertainty rather than treating the gap as an expected difference in what two measurements are actually measuring.